Mobia Medical, Inc. 8-K

What Happened
Mobia Medical, Inc. (MOBI) filed an 8-K reporting that on July 14, 2026 the Board increased from six to seven members and appointed Reza Zadno, Ph.D., as a Class III director. Dr. Zadno’s term runs until Mobia’s 2029 annual meeting of stockholders (or until a successor is elected). The Board also named him to the Compensation Committee and determined he qualifies as an independent director under SEC rules and Nasdaq listing standards.

Key Details

• Appointment date: July 14, 2026; Board size increased from 6 to 7.
• Director class/term: Class III, term expiring at the 2029 annual meeting.
• Committee change: Dr. William Harrington resigned from the Compensation Committee; the committee now is Casey Tansey (chair), Dana Mead and Reza Zadno.
• Background: Dr. Zadno was CEO of PROCEPT BioRobotics (Feb 2020–Sep 2025) and Avedro, Inc. (Sep 2016–Nov 2020); served on multiple medical device/biotech boards; Operating Partner at Jolt Capital since Feb 2026; Special Advisor to the American Academy of Ophthalmology since Jan 2024; Ph.D. and M.Sc. from École Nationale Supérieure des Mines de Paris.
• Compensation and conflicts: He will receive Mobia’s standard non-employee director compensation and Mobia expects to enter its usual indemnification agreement. No related-party transactions reportable under Item 404 were disclosed.

Why It Matters
This filing updates investors on a board-level governance change that adds an independent director with executive and board experience in medical devices and ophthalmology—areas relevant to Mobia’s business. The addition and committee appointment could influence corporate oversight, especially compensation governance, but the filing discloses no related-party transactions or special arrangements tied to the appointment.